Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Other Operating Expenses (2016 - 2020)

VYNE Therapeutics' Other Operating Expenses history spans 4 years, with the latest figure at $139.1 million for Q2 2020.

  • For Q2 2020, Other Operating Expenses changed N/A year-over-year to $139.1 million; the TTM value through Mar 2021 reached $139.1 million, up 361.04%, while the annual FY2020 figure was $139.1 million, N/A changed from the prior year.
  • Other Operating Expenses reached $139.1 million in Q2 2020 per VYNE's latest filing, up from -$37.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $139.1 million in Q2 2020 to a low of -$37.6 million in Q1 2020.
  • Average Other Operating Expenses over 4 years is $7.3 million, with a median of -$14.5 million recorded in 2018.
  • Peak YoY movement for Other Operating Expenses: fell 17.45% in 2019, then fell 10.46% in 2020.
  • A 4-year view of Other Operating Expenses shows it stood at $5.4 million in 2016, then plummeted by 347.71% to -$13.3 million in 2018, then decreased by 17.45% to -$15.6 million in 2019, then skyrocketed by 989.49% to $139.1 million in 2020.
  • Per Business Quant, the three most recent readings for VYNE's Other Operating Expenses are $139.1 million (Q2 2020), -$37.6 million (Q1 2020), and -$15.6 million (Q4 2019).